Aclarion announces major commercial milestone with completion of 1,000 Nociscan exams
Nociscan orders accelerated 2.5x for the last 250 scans compared to the first 250 scans
Further acceleration in scan volumes is expected as MRIs are activated for the recently completed panel of 10 Key Opinion Leader (KOL) surgeons
All commercial Nociscans to date have been completed on Siemens MRI scanners, with additional acceleration in volumes expected as Philips scanners come on board
BROOMFIELD, CO, November 27, 2023 (GLOBE NEWSWIRE) – via NewMediaWire —Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that uses biomarkers and proprietary enhanced intelligence algorithms to help physicians identify the location of chronic low back pain, today announced it has completed 1,000 commercial Nociscan studies.
“This milestone in itself is significant, but the pace of our commercial adoption is the most exciting aspect of reaching 1,000 commercial scans,” said Brent Ness, CEO of Aclarion. “For context, 36% of these 1,000 studies were conducted in the last twelve months, demonstrating the adoption our strategy has delivered on our journey to a standard of care. As more imaging locations are added and KOLs continue to access Nociscan, we expect to reach the 2,000 scans milestone even faster.”
“This achievement reinforces Aclarion’s clear leadership in the evolving field of augmented intelligence and the renaissance in MR spectroscopy,” said Ryan Bond, Chief Strategy Officer at Aclarion. “Nociscan is the first of its kind, evidence-based SaaS platform that turns volumes of complex data into a clear, streamlined report that efficiently communicates individualized biomarker data to help physicians optimize treatment strategies for patients suffering from chronic low back pain. This is an important commercial milestone for our physician customers, their patients and our team.”
Worldwide, 266 million people suffer from degenerative spinal disorders and lower back pain1. Conventional imaging and diagnostics provide valuable structural information but struggle to identify the source of the pathogenic pain. Low surgical success rates (41-57%)2.3 especially for patients suffering from discogenic chronic low back pain (DCLP). Of all disease conditions, low back and neck pain are responsible for the highest healthcare expenditures in the US1.
Aclarion’s disruptive innovation, Nociscan, emerged over a decade of development. Aclarion’s patent portfolio includes 22 U.S. patents, 17 international patents, 6 pending U.S. patent applications and 7 pending international patent applications, including patents and patent applications exclusively licensed by Regents of the University of California.
Nociscan is currently available from imaging facilities using select models of Siemens 1.5T and 3T magnetic resonance spectroscopy. For more information please contact info@aclarion.com.
About Aclarion, Inc.
Aclarion is a healthcare technology company that uses magnetic resonance spectroscopy (MRS), proprietary signal processing techniques, biomarkers and enhanced intelligence algorithms to optimize clinical treatments. The company is entering the chronic low back pain market for the first time with Nociscan, the first evidence-based SaaS platform that helps physicians non-invasively distinguish between painful and non-painful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers shown to be associated with disc pain. Biomarker data is fed into proprietary algorithms to indicate whether a disc may be a source of pain. When combined with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving clinicians clarity to optimize treatment strategies. For more information please visit www.aclarion.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on management’s current plans and expectations and are subject to a number of uncertainties and risks that could materially affect the company’s current plans and expectations, as well as its future results of operations and financial condition. These and other risks and uncertainties are discussed in more detail in our filings with the Securities and Exchange Commission. Readers are encouraged to read the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, as well as other disclosures in the prospectus and subsequent filings with the Securities and Exchange Commission. . Forward-looking statements in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor contacts:
Kirin M. Smith
PCG Advice, Inc.
646.823.8656
ksmith@pcgadvisory.com
Media contacts:
Jodi Lamberti
SPRIG advice
612.812.7477
jodi@sprigconsulting.com
[1] Ravindra VM, Global Spine Journal (2018) 8(8): 784-794
[2] Wei J, Song Y, et al. Comparison of artificial total disc replacement versus fusion for lumbar disc disease: a meta-analysis of randomized controlled trials. Int Orthop. 2013; 37(7):1315-1325
[3] Ibrahim T, Tieyjeh IM, et al. Surgical versus nonsurgical treatment of chronic low back pain: a meta-analysis of randomized trials. Int Orthop. 2008; 32(1):107-113
